AbbVie Inc., North Chicago, USA.
Invicro - London, Burlington Danes Building, Du Cane Road, W12 0NN, London, UK.
Brain Imaging Behav. 2019 Apr;13(2):354-365. doi: 10.1007/s11682-018-9967-0.
As drug discovery and development in Neuroscience push beyond symptom management to disease modification, neuroimaging becomes a key area of translational research that enables measurements of the presence of drugs and downstream physiological consequences of drug action within the living brain. As such, neuroimaging can be used to help optimize decision-making processes throughout the various phases of drug development. Positron Emission Tomography (PET) is a functional imaging technique that allows the quantification and visualization of biochemical processes, by monitoring the time dependent distribution of molecules labelled with short-lived positron-emitting isotopes. This review focuses on the application of PET to support CNS drug development, particularly in the early clinical phases, by allowing us to measure tissue exposure, target engagement, and pharmacological activity. We will also discuss the application of PET imaging as tools to image the pathological hallmarks of disease and evaluate the potential disease-modifying effect of candidate drugs in slowing disease progression.
随着神经科学领域的药物研发从症状管理推进到疾病修饰，神经影像学成为转化研究的一个关键领域，使我们能够在活体大脑中测量药物的存在以及药物作用的下游生理后果。因此，神经影像学可用于帮助优化药物开发各个阶段的决策过程。正电子发射断层扫描（PET）是一种功能成像技术，通过监测用短寿命正电子发射同位素标记的分子的时间依赖性分布，允许定量和可视化生化过程。本综述重点介绍了 PET 在支持中枢神经系统药物开发中的应用，特别是在早期临床阶段，使我们能够测量组织暴露、靶标结合和药理活性。我们还将讨论 PET 成像作为工具在疾病的病理特征成像中的应用，并评估候选药物在减缓疾病进展方面的潜在疾病修饰作用。
